No Data
US Stock MarketDetailed Quotes
TPST Tempest Therapeutics
Watchlist
1.190
-0.150-11.19% Close 06/09 16:00 ET
1.200+0.010+0.84%
Post 16:08 ET
1.380High1.190Low138.94KVolume
1.380Open1.340Pre Close173.96KTurnover3.60%Turnover RatioLossP/E (TTM)13.79MMarket Cap4.21452wk HighLossP/E (Static)11.59MShares1.06052wk Low1.26P/B4.59MFloat Cap260.100Historical High--Dividend TTM3.86MShs Float1.060Historical Low--Div YieldTTM14.18%Amplitude1.252Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
News
H.C. Wainwright Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
Tempest to Present at the Jefferies Global Healthcare Conference
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Analyst Ratings for Tempest Therapeutics
Over the past 3 months, 5 analysts have published their opinion on Tempest Therapeutics (NASDAQ:TPST) stock. These analysts are typically employed by large Wall Street banks and tasked with understand
Comments
Read more
RipperOP : Keep eye on this…..it’s up to something